# Constructing a novel prognostic model for triple-negative breast cancer based on genes associated with vasculogenic mimicry

**Authors:** Yu Ren, Luyi Feng, Zhihua Tan, Fulin Zhou, Shu Liu

PMC · DOI: 10.18632/aging.205806 · Aging (Albany NY) · 2024-05-08

## TL;DR

This study identifies three genes linked to vasculogenic mimicry in triple-negative breast cancer, creating a new model to predict prognosis and treatment response.

## Contribution

A novel prognostic model for TNBC using VM-related genes KCND2, NRP1, and VSTM4 is developed and validated.

## Key findings

- 235 genes were found to be connected to the complement and coagulation cascade pathways.
- The risk score model using KCND2, NRP1, and VSTM4 showed good validation results with pathological T stage.
- Low-risk group showed better immunotherapy sensitivity, and KCND2 knockdown reduced TNBC cell proliferation and migration.

## Abstract

Background: Research has shown a connection between vasculogenic mimicry (VM) and cancer progression. However, the functions of genes related to VM in the emergence and progression of TNBC have not been completely elucidated.

Methods: A survival risk model was constructed by screening biomarkers using DESeq2 and WGCNA based on public TNBC transcriptome data. Furthermore, gene set enrichment analysis was performed, and tumor microenvironment and drug sensitivity were analyzed. The selected biomarkers were validated via quantitative PCR detection, immunohistochemical staining, and protein detection in breast cancer cell lines. Biomarkers related to the proliferation and migration of TNBC cells were validated via in vitro experiments.

Results: The findings revealed that 235 target genes were connected to the complement and coagulation cascade pathways. The risk score was constructed using KCND2, NRP1, and VSTM4. The prognosis model using the risk score and pathological T stage yielded good validation results. The clinical risk of TNBC was associated with the angiogenesis signaling pathway, and the low-risk group exhibited better sensitivity to immunotherapy. Quantitative PCR and immunohistochemistry indicated that the expression levels of KCND2 in TNBC tissues were higher than those in adjacent nontumor tissues. In the TNBC cell line, the protein expression of KCND2 was increased. Knockdown of KCND2 and VSTM4 inhibited the proliferation and migration of TNBC cells in vitro.

Conclusions: In this study, three VM-related biomarkers were identified, including KCND2, NRP1, and VSTM4. These findings are likely to aid in deepening our understanding of the regulatory mechanism of VM in TNBC.

## Linked entities

- **Genes:** KCND2 (potassium voltage-gated channel subfamily D member 2) [NCBI Gene 3751], NRP1 (neuropilin 1) [NCBI Gene 8829], VSTM4 (V-set and transmembrane domain containing 4) [NCBI Gene 196740]
- **Diseases:** triple-negative breast cancer (MONDO:0005494), breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** VSTM4 (V-set and transmembrane domain containing 4) [NCBI Gene 196740] {aka C10orf72}, NRP1 (neuropilin 1) [NCBI Gene 8829] {aka BDCA4, CD304, NP1, NRP, VEGF165R}, KCND2 (potassium voltage-gated channel subfamily D member 2) [NCBI Gene 3751] {aka KV4.2, RK5}
- **Diseases:** breast cancer (MESH:D001943), cancer (MESH:D009369), triple-negative breast cancer (MESH:D064726)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11132006/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11132006/full.md

## References

68 references — full list in the complete paper: https://tomesphere.com/paper/PMC11132006/full.md

---
Source: https://tomesphere.com/paper/PMC11132006